Terms: = Head and neck cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Treatment
983 results:
1. Promising Approaches in Plant-Based Therapies for Thyroid cancer: An Overview of In Vitro, In Vivo, and Clinical Trial Studies.
Kaczmarzyk I; Nowak-Perlak M; Woźniak M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674046
[TBL] [Abstract] [Full Text] [Related]
2. Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches.
Wang H; Zhang C; Li Q; Tian T; Huang R; Qiu J; Tian R
BMC Cancer; 2024 Apr; 24(1):427. PubMed ID: 38589799
[TBL] [Abstract] [Full Text] [Related]
3. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ata initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract] [Full Text] [Related]
4. Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation.
Zhang K; Wang X; Wei T; Li Z; Zhu J; Chen YW
Front Endocrinol (Lausanne); 2024; 15():1347362. PubMed ID: 38544687
[TBL] [Abstract] [Full Text] [Related]
5. Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.
Hu J; Liu K; Ghosh C; Khaket TP; Shih H; Kebebew E
J Exp Clin Cancer Res; 2024 Mar; 43(1):85. PubMed ID: 38500204
[TBL] [Abstract] [Full Text] [Related]
6. Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies.
Kuang BH; Zhang WX; Lin GH; Fu C; Cao RB; Wang BC
Front Endocrinol (Lausanne); 2024; 15():1345203. PubMed ID: 38469143
[TBL] [Abstract] [Full Text] [Related]
7. The value of multimodal treatment in anaplastic thyroid cancer patients with distant metastasis.
Guo H; Lin H
BMC Surg; 2024 Mar; 24(1):79. PubMed ID: 38438944
[TBL] [Abstract] [Full Text] [Related]
8. MACE and Hyperthyroidism Treated With Medication, Radioactive Iodine, or Thyroidectomy.
Peng CC; Lin YJ; Lee SY; Lin SM; Han C; Loh CH; Huang HK; Pearce EN
JAMA Netw Open; 2024 Mar; 7(3):e240904. PubMed ID: 38436957
[TBL] [Abstract] [Full Text] [Related]
9. ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.
Lin TY; Jia JS; Luo WR; Lin XL; Xiao SJ; Yang J; Xia JW; Zhou C; Zhou ZH; Lin SJ; Li QW; Yang ZZ; Lei Y; Yang WQ; Shen HF; Huang SH; Wang SC; Chen LB; Yang YL; Xue SW; Li YL; Dai GQ; Zhou Y; Li YC; Wei F; Rong XX; Luo XJ; Zhao BX; Huang WH; Xiao D; Sun Y
J Exp Clin Cancer Res; 2024 Feb; 43(1):62. PubMed ID: 38419081
[TBL] [Abstract] [Full Text] [Related]
10. Second radioiodine treatment in patients with differentiated thyroid carcinoma: Causes and effects.
Sicilia Pozo MLN; Pena Pardo FJ; Amo Salas M; Cruz Montijano M; Torres Hernández J; Padilla Bermejo A; Montalbán Méndez C; Zhao Montero M; Soriano Castrejón Á; García Vicente AM
Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):4-11. PubMed ID: 38388076
[TBL] [Abstract] [Full Text] [Related]
11. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
Soll D; Bischoff P; Frisch A; Jensen M; Karadeniz Z; Mogl MT; Horst D; Penzkofer T; Spranger J; Keilholz U; Mai K
BMC Endocr Disord; 2024 Feb; 24(1):25. PubMed ID: 38383419
[TBL] [Abstract] [Full Text] [Related]
12. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B; Pons-Tostivint E; Park K; Hartl S; Forde PM; Hochmair MJ; Awad MM; Thomas M; Goss G; Wheatley-Price P; Shepherd FA; Florescu M; Cheema P; Chu QSC; Kim SW; Morgensztern D; Johnson ML; Cousin S; Kim DW; Moskovitz MT; Vicente D; Aronson B; Hobson R; Ambrose HJ; Khosla S; Reddy A; Russell DL; Keddar MR; Conway JP; Barrett JC; Dean E; Kumar R; Dressman M; Jewsbury PJ; Iyer S; Barry ST; Cosaert J; Heymach JV
Nat Med; 2024 Mar; 30(3):716-729. PubMed ID: 38351187
[TBL] [Abstract] [Full Text] [Related]
13. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic
Tahara M; Kiyota N; Imai H; Takahashi S; Nishiyama A; Tamura S; Shimizu Y; Kadowaki S; Ito KI; Toyoshima M; Hirashima Y; Ueno S; Sugitani I
Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
[No Abstract] [Full Text] [Related]
14. Assessment of quality of life in thyroid cancer patients using the EORTC thyroid-specific questionnaire: a prospective cross-sectional study.
Thiagarajan S; Fatehi K; Menon N; Sawant M; Pal A
Eur Arch Otorhinolaryngol; 2024 Apr; 281(4):1953-1960. PubMed ID: 38308761
[TBL] [Abstract] [Full Text] [Related]
15. Progress in diagnosing and treating thyroid squamous cell carcinoma under the 5th edition of WHO classification.
Ding W; Gao X; Ran X
Front Endocrinol (Lausanne); 2023; 14():1273472. PubMed ID: 38303977
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of the Therapeutic Effects of Harmine on Anaplastic Thyroid cancer Cells.
Baldini E; Cardarelli S; Campese AF; Lori E; Fallahi P; Virili C; Forte F; Pironi D; Di Matteo FM; Palumbo P; Costanzo ML; D'Andrea V; Centanni M; Sorrenti S; Antonelli A; Ulisse S
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256193
[TBL] [Abstract] [Full Text] [Related]
17. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
[No Abstract] [Full Text] [Related]
18. [Diagnostic Value of American Thyroid Association Guidelines,American College of Radiology Thyroid Imaging Reporting and Data System,and Chinese Thyroid Imaging Reporting and Data System Alone and Combined With BRAF
Lin Y; Luo YK; Li J; Ren XY; Wang HW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):921-928. PubMed ID: 38173102
[TBL] [Abstract] [Full Text] [Related]
19. Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma.
De Martino M; Pellecchia S; Decaussin-Petrucci M; Testa D; Meireles Da Costa N; Pallante P; Chieffi P; Fusco A; Esposito F
Cell Cycle; 2023; 22(23-24):2552-2565. PubMed ID: 38165007
[TBL] [Abstract] [Full Text] [Related]
20. Inhibition of MEK Signaling Attenuates cancer Stem Cell Activity in Anaplastic Thyroid cancer.
Kimura T; Doolittle WKL; Kruhlak M; Zhao L; Hwang E; Zhu X; Tang B; Wolcott KM; Cheng SY
Thyroid; 2024 Apr; 34(4):484-495. PubMed ID: 38115586
[No Abstract] [Full Text] [Related]
[Next]